BioNTech SE American Depositary Share
BioNTech SE American Depositary S.../ US09075V1026 /
BNTX
16.05.2024 21:59:50
|
Изменение
+0.82
|
Объем сделки |
Бид- |
Предложение- |
Рыночная капитализация |
Дивидендная доходность |
Коэффициент Цена/Доход |
92.99USD
|
+0.89%
|
17,362 Оборот: 1.61 млн |
-Величина цены спроса: - |
-Величина цены предложения: - |
-USD |
- |
- |
Описание деятельности
Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.
Правление & Наблюдательный совет
Исполнительный директор |
Ugur Sahin |
Правление |
Jens Holstein, Özlem Türeci, Ryan Richardson, Sean Marett, Sierk Poetting |
Наблюдательный совет |
Helmut Jeggle, Michael Motschmann, Prof. Christoph Huber, Ulrich Wandschneider |
Данные компании
Имя: |
BioNTech SE |
Адрес: |
An der Goldgrube 12,DE-55131 Mainz |
Телефон: |
+49-6131-9084-0 |
Факс: |
+49-6131-9084-390 |
E-mail: |
info@biontech.de
|
Интернет: |
https://biontech.de/de |
Индустрия: |
Biotechnology |
Сектор: |
Biotechnology |
Подсектор: |
Biotechnology |
Конец финансового года: |
31.12 |
Акции в свободном обращении: |
- |
Дата IPO: |
- |
Календарь компании
CW 20 | 17.05.2024
General Shareholder Meeting
|
CW 32 | 05.08.2024
Interim Report 2nd Quarter/6 Months
|
CW 45 | 04.11.2024
Interim Report 3rd Quarter/9 Months
|
Основные акционеры
AT Impf GmbH |
|
50.33% |
Freefloat |
|
19.70% |
Medine GmbH |
|
18.38% |
MIG Verwaltungs AG |
|
5.98% |
FMR LLC |
|
5.61% |